I3 Advisory Board
The i-Cubed™ Advisory Board (AB) includes experts in medicine, clinical research, technology, and finance who are all committed to helping advance our goals. The AB provides high-level, independent, strategic guidance to our leadership team. Members also help strengthen partnerships with research and funding communities, and provide input into our strategy, priorities, policies, processes, and resources.
Adrian Hernandez, MD
Executive Director, Duke Clinical Research Institute (DCRI)
Dr. Adrian Hernandez is the Executive Director of Duke Clinical Research Institute (DCRI), Vice Dean of the Duke University School of Medicine and a Distinguished Professor of Duke Health Cardiology. He provides visionary and strategic direction to the DCRI, supports and strengthens its research and teaching agendas, and continues to raise its national and international profile.
Dr. Hernandez is an internationally recognized leader in clinical research ranging from health services and policy research to clinical trials. He has served as the steering committee chair or principal investigator of multiple large studies and networks often leveraging new methods to accelerate evidence generation and implementation. Dr. Hernandez has over 800 published articles and is an elected member of the American Society of Clinical Investigation and Association of American Physicians.
He received his medical degree from the University of Texas-Southwestern at Dallas and completed his residency in internal medicine at the University of California San Francisco School of Medicine, before completing a fellowship in cardiology at Duke University.
Adrian Hernandez, MD
Executive Director, Duke Clinical Research Institute (DCRI)
Mary E. Klotman, MD
Dean, Duke School of Medicine, Executive Vice President for Health Affairs, Duke University
Mary E. Klotman, MD is a nationally recognized leader in academic medicine. She was appointed as Duke's first executive vice president for health affairs and assumed her new role on July 1, 2023. Concurrently, she is serving a second five-year term as dean of the School of Medicine. Previously Klotman served as chair of the Department of Medicine in the Duke University School of Medicine for seven years.
Klotman earned undergraduate and medical degrees from Duke University. She completed internal medicine residency and a fellowship in infectious diseases in the Duke Department of Medicine before joining the faculty as assistant professor of medicine. In 1991 she joined the National Institutes of Health, where she was a member of the Public Health Service.
Before returning to Duke in 2010, Klotman was the Irene and Dr. Arthur M. Fishberg Professor of Medicine and served as chief of the Division of Infectious Diseases at Mount Sinai School of Medicine. She was also co-director of Mount Sinai's Global Health and Emerging Pathogens Institute.
Klotman's research interests focus on the molecular pathogenesis of Human Immunodeficiency Virus 1 (HIV-1) infection. Among many contributions, Klotman and her team demonstrated that HIV resides in and evolves separately in kidney cells, a critical step in HIV-associated kidney disease. Election to the National Academy of Medicine and councilor of the Association of American Physicians stand out among her many accolades.
Mary E. Klotman, MD
Executive Vice President for Health Affairs, Duke University
Esther Krofah, MPP
Executive Vice President, Milken Institute (MI Health)
Esther Krofah is the Executive Vice President of MI Health at the Milken Institute. She has extensive experience in the government, nonprofit, and for-profit sectors, where she has led efforts to bring together diverse stakeholder groups to solve critical issues and achieve shared goals that improve the lives of patients.
Prior to her current role, Krofah was the Director of Public Policy leading GlaxoSmithKline's engagement with the US Department of Health and Human Services (HHS) and relevant executive branch agencies on broad healthcare policy issues. She also served as the Deputy Director of HHS' Office of Health Reform, where she led the development of policy positions for significant regulatory priorities, including the health insurance marketplaces.
Krofah received a BA from Duke University and a master's in public policy from the Harvard University John F. Kennedy School of Government.
Esther Krofah, MPP
Executive Vice President, Milken Institute (MI Health)
Craig Lipset, MPH
Founder, Clinical Innovation Partners
Craig Lipset is a leader in clinical research and medicine development. He is the Founder of Clinical Innovation Partners, where he advises technology and biopharmaceutical companies, leading universities, and the venture community seeking to develop and implement innovative solutions for clinical research. Craig is also the Co-Founder and Co-Chair of the Decentralized Trials & Research Alliance, the world's largest non-profit organization dedicated to the adoption of more accessible clinical research participation. Craig has served on the Board of Directors for the Foundation for Sarcoidosis Research, the Board of Directors for the MedStar Health Research Institute, and the Editorial Board for Therapeutic Innovation & Regulatory Science. He is an Adjunct Assistant Professor in Health Informatics at Rutgers University, and an Adjunct Instructor at the University of Rochester Center for Health + Technology.
Craig previously served as Head of Clinical Innovation at Pfizer, where he led digital initiatives, patient engagement, and collaborations across all therapeutic areas around the globe. During that tenure, he launched multiple "industry firsts" - from the first fully remote/virtual clinical trial for a new medicine to the first returning of results and data to research participants.
Craig Lipset, MPH
Founder, Clinical Innovation Partners
Michelle McMurry-Heath, MD, PhD
Former CEO, Biotechnology Innovation Organization (BIO), Visiting Fellow, Duke-Margolis Center for Health Policy
Michelle McMurry-Heath is a medical doctor, immunologist, and former CEO of the Biotechnology Innovation Organization (BIO), the world's largest biotechnology advocacy group, representing nearly 1,000 life sciences companies and organizations from 30 countries. She is currently a Visiting Fellow at the Duke-Margolis Center for Health Policy.
McMurry-Heath has extensive experience in the government, nonprofit, and for-profit sectors, including serving as the Associate Center Director for Science in the US Food and Drug Administration (FDA) Center for Diagnostics and Radiological Health. She formerly led the regulatory and clinical teams of Johnson & Johnson's Medical Device sector. McMurry-Heath received her undergraduate degree from Harvard University in biochemistry and her M.D. and Ph.D. in immunology from Duke University.
Michelle McMurry-Heath, MD, PhD
Former CEO, Biotechnology Innovation Organization (BIO), Visiting Fellow, Duke-Margolis Center for Health Policy
Clive Meanwell, MD
CEO, Population Health Investment Co Inc.
Dr. Clive A. Meanwell is Founder and Executive Chairman of Population Health Partners, L.P. He is Vice-Chairman and a member of the Board of Directors of BB Biotech AG as well as a member of the Board of Directors of Fractyl Health Inc., Invivyd, Inc., Hugo Health, Inc. and Saama Technologies, Inc. In 1996, Dr. Meanwell founded The Medicines Company and from then until January 2020 was a member of the Board of Directors and held a range of leadership positions including Chairman, Executive Chairman, Chief Executive and Chief Innovation Officer. From 1995 until 1996, he was a Founding Partner and Managing Director of MPM Capital L.P. Earlier in his career, Dr. Meanwell held various positions at Hoffmann-La Roche in Basel, Switzerland and Palo Alto, California. He received his MD and PhD from the University of Birmingham in the UK where he also trained in medical oncology.
Clive Meanwell, MD
CEO, Population Health Investment Co Inc.
Jessica L. Mega, MD, MPH
Director, Boston Scientific, Co-Founder, Verily
Jessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health care. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily, and she is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women's Hospital, Dr. Mega led large, international, randomized clinical trials evaluating novel therapies. She also directed the TIMI Study Group's Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor's Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women's Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).
Jessica L. Mega, MD, MPH
Director, Boston Scientific, Co-Founder, Verily
Al Richmond, MSW
Executive Director, Community-Campus Partnerships for Health
Al Richmond MSW, Executive Director of Community-Campus Partnerships for Health (CCPH), is a global leader in advocating for the increased role of communities in research. Richmond has played significant roles locally and internationally to advance community engagement in health research, including NIH's Clinical and Translational Science Award, RADx® Underserved Populations and the Community Engagement Alliance (CEAL).
As Executive Director of CCPH, Richmond is advancing the organization's commitment to health equity through deepening our collective understanding and appreciation of the role of authentic partnerships. Richmond holds an MSW from The Ohio State University. He is a certified facilitator for the Intercultural Developmental Inventory, ToP Facilitation Method and as a Business Coach.
Al Richmond, MSW
Executive Director, Community-Campus Partnerships for Health
Joanne Waldstreicher, MD
Independent Director, Becton Dickinson and Structure Therapeutics
Joanne Waldstreicher currently serves as an independent director on the boards of Becton Dickinson and Structure Therapeutics, as well as an independent consultant and advisor. Prior to this, she served as the chief medical officer of Johnson & Johnson (J&J) from 2012 to 2023, where she provided visionary strategic and operational leadership, with global responsibility for safety, epidemiology, regulatory and clinical operations transformation, bioethics and late-stage pipeline program review.
Dr. Waldstreicher has authored more than 55 research publications, holds numerous patents and has established herself as a thought leader in evidence and science-based product development and decision-making, driven by patient needs and bioethical values. She brings more than 30 years of experience in clinical and strategic leadership, along with a deep knowledge of the healthcare industry and regulatory and safety expertise.
Dr. Waldstreicher received both the Jonas Salk and Belle Zeller scholarships from the City University of New York and graduated Summa Cum Laude from Brooklyn College. Dr. Waldstreicher graduated Cum Laude from Harvard Medical School in 1987, and completed her internship and residency at Boston's Beth Israel Hospital, and her endocrinology fellowship at Massachusetts General Hospital.
Joanne Waldstreicher, MD
Independent Director, Becton Dickinson and Structure Therapeutics
Robert Sanders Williams, MD
Former Dean, Duke University School of Medicine
Robert Sanders "Sandy" Williams is a medical doctor and former Dean of the Duke University School of Medicine. He is also the former President of the Gladstone Institutes in San Francisco and a Professor of Medicine at the University of California, San Francisco.
Williams has extensive experience in academia and in the healthcare industry, having served as a professor of medicine at Duke from 1980 to 1990 and later at the University of Texas Southwestern Medical Center, where he directed cardiovascular research and clinical care. He was the founding Dean of the Duke-NUS Graduate Medical School of Singapore and a negotiator for major Duke programs in China. He has served as a Director of public companies Bristol-Myers Squibb, Amgen, LabCorp, and Tenaya Therapeutics. Williams has received numerous awards, including election to the US National Academy of Medicine.
He received his medical degree from Duke, completed his residency in internal medicine at the Massachusetts General Hospital in Boston, cardiology fellowship at Duke, and laboratory fellowships in biochemistry/molecular biology at Duke, Oxford University, and the Cold Spring Harbor Laboratory.
Robert Sanders Williams, MD
Former Dean, Duke University School of Medicine